Published in Blood on March 07, 2006
Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell (2007) 4.21
Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B. Genes Dev (2008) 2.68
The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood (2011) 2.23
Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia. Proc Natl Acad Sci U S A (2008) 2.10
BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia. Nat Chem Biol (2012) 1.77
Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice. Blood (2012) 1.67
Critical requirement for Stat5 in a mouse model of polycythemia vera. Blood (2011) 1.48
A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain. Nat Struct Mol Biol (2010) 1.47
Maximal STAT5-induced proliferation and self-renewal at intermediate STAT5 activity levels. Mol Cell Biol (2008) 1.33
A chemical biology approach to developing STAT inhibitors: molecular strategies for accelerating clinical translation. Oncotarget (2011) 1.26
Aberrant cytokine signaling in leukemia. Oncogene (2007) 1.20
Myeloproliferative disease induced by TEL-PDGFRB displays dynamic range sensitivity to Stat5 gene dosage. Blood (2007) 1.19
Regulation of myeloproliferation and M2 macrophage programming in mice by Lyn/Hck, SHIP, and Stat5. J Clin Invest (2008) 1.16
Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade. Blood (2008) 1.16
Oncogenic signaling: new insights and controversies from chronic myeloid leukemia. J Exp Med (2007) 1.13
STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia. Oncotarget (2012) 1.12
JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo. Blood (2014) 1.08
The role of the Janus-faced transcription factor PAX5-JAK2 in acute lymphoblastic leukemia. Blood (2014) 0.94
STAT signaling in the pathogenesis and treatment of myeloid malignancies. JAKSTAT (2012) 0.92
Mouse models as tools to understand and study BCR-ABL1 diseases. Am J Blood Res (2011) 0.88
Transforming and tumorigenic activity of JAK2 by fusion to BCR: molecular mechanisms of action of a novel BCR-JAK2 tyrosine-kinase. PLoS One (2012) 0.88
Bmi1 reprograms CML B-lymphoid progenitors to become B-ALL-initiating cells. Blood (2011) 0.87
BCR-ABL affects STAT5A and STAT5B differentially. PLoS One (2014) 0.83
Targeted blockage of signal transducer and activator of transcription 5 signaling pathway with decoy oligodeoxynucleotides suppresses leukemic K562 cell growth. DNA Cell Biol (2010) 0.83
Regulation of the interferon regulatory factor-8 (IRF-8) tumor suppressor gene by the signal transducer and activator of transcription 5 (STAT5) transcription factor in chronic myeloid leukemia. J Biol Chem (2014) 0.82
The oncogenic FIP1L1-PDGFRα fusion protein displays skewed signaling properties compared to its wild-type PDGFRα counterpart. JAKSTAT (2015) 0.81
STAT5-mediated self-renewal of normal hematopoietic and leukemic stem cells. JAKSTAT (2012) 0.81
Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia. J Clin Invest (2016) 0.81
Stat5-deficient hematopoiesis is permissive for Myc-induced B-cell leukemogenesis. Oncotarget (2015) 0.80
Regulation of hTERT by BCR-ABL at multiple levels in K562 cells. BMC Cancer (2011) 0.80
C/EBPβ promotes BCR-ABL-mediated myeloid expansion and leukemic stem cell exhaustion. Leukemia (2012) 0.78
Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia. Mol Cancer Ther (2015) 0.77
BM microenvironmental protection of CML cells from imatinib through Stat5/NF-κB signaling and reversal by Wogonin. Oncotarget (2016) 0.76
Ursolic acid-mediated apoptosis of K562 cells involves Stat5/Akt pathway inhibition through the induction of Gfi-1. Sci Rep (2016) 0.76
Elevated PTPN2 expression is associated with inferior molecular response in de-novo chronic myeloid leukaemia patients. Leukemia (2013) 0.75
Tyrosine 625 plays a key role and cooperates with tyrosine 630 in MPL W515L-induced signaling and myeloproliferative neoplasms. Cell Biosci (2016) 0.75
Overview of the Use of Murine Models in Leukemia and Lymphoma Research. Front Oncol (2017) 0.75
Bcr-abl regulates Stat5 through Shp2, the interferon consensus sequence binding protein (Icsbp/Irf8), growth arrest specific 2 (Gas2) and calpain. Oncotarget (2016) 0.75
Novel iodoacetamido benzoheterocyclic derivatives with potent antileukemic activity are inhibitors of STAT5 phosphorylation. Eur J Med Chem (2015) 0.75
Intramolecular hydrophobic interactions are critical mediators of STAT5 dimerization. Sci Rep (2016) 0.75
Identification and functional characterization of the miRNA-gene regulatory network in chronic myeloid leukemia lineage negative cells. Sci Rep (2016) 0.75
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 24.51
Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci U S A (1993) 22.33
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (2001) 20.30
Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science (1990) 10.59
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med (2002) 8.86
Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood (1998) 6.81
Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell (1998) 5.92
Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev (1997) 5.57
Versatile retroviral vectors for potential use in gene therapy. Gene Ther (1994) 5.33
Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation. Mol Cell Biol (2004) 4.45
The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med (1999) 4.06
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood (2002) 4.00
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia (2002) 3.90
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood (2002) 3.60
kat: a high-efficiency retroviral transduction system for primary human T lymphocytes. Blood (1994) 2.94
Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med (1996) 2.68
P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem (1996) 2.47
Stat5 tetramer formation is associated with leukemogenesis. Cancer Cell (2005) 2.26
A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9. Proc Natl Acad Sci U S A (2002) 2.19
Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene (1996) 2.17
bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. EMBO J (1990) 2.00
Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene (2003) 1.96
Reduced lymphomyeloid repopulating activity from adult bone marrow and fetal liver of mice lacking expression of STAT5. Blood (2002) 1.96
Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med (2003) 1.95
Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med (2000) 1.89
Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol (2004) 1.83
Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of stat5. Blood (2000) 1.74
Bcr/Abl activates transcription of the Bcl-X gene through STAT5. Blood (2000) 1.64
Antiapoptotic activity of Stat5 required during terminal stages of myeloid differentiation. Genes Dev (2000) 1.61
Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J Exp Med (1999) 1.61
Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol (1997) 1.59
The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia. Blood (2003) 1.53
STAT5A-deficient mice demonstrate a defect in granulocyte-macrophage colony-stimulating factor-induced proliferation and gene expression. Blood (1997) 1.53
STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood (2000) 1.44
Dominant negative mutants implicate STAT5 in myeloid cell proliferation and neutrophil differentiation. Blood (1999) 1.42
Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571. Blood (2001) 1.41
Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling. J Exp Med (2000) 1.38
Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene (2002) 1.38
Abelson antigen: a viral tumor antigen that is also a differentiation antigen of BALB/c mice. Proc Natl Acad Sci U S A (1978) 1.32
STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells. Blood (1999) 1.29
Cell intrinsic defects in cytokine responsiveness of STAT5-deficient hematopoietic stem cells. Blood (2002) 1.25
STAT5-Dependent CyclinD1 and Bcl-xL expression in Bcr-Abl-transformed cells. Mol Cell Biol Res Commun (2000) 1.24
Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era. Leuk Res (2004) 1.19
BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability. Oncogene (2002) 1.12
Hematopoietic-repopulating defects from STAT5-deficient bone marrow are not fully accounted for by loss of thrombopoietin responsiveness. Blood (2003) 1.05
Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib. Eur J Haematol (2003) 1.05
Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment. Semin Hematol (2003) 1.02
BCR/abl leads to the constitutive activation of Stat proteins, and shares an epitope with tyrosine phosphorylated Stats. Leukemia (1996) 1.02
Signal transduction pathways regulated by prolactin and Src result in different conformations of activated Stat5b. J Biol Chem (2003) 1.01
BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration. Cancer Genet Cytogenet (2002) 0.98
Immunoreactivity of Stat5 phosphorylated on tyrosine as a cell-based measure of Bcr/Abl kinase activity. Cytometry A (2003) 0.98
Prolactin stimulates serine/tyrosine phosphorylation and formation of heterocomplexes of multiple Stat5 isoforms in Nb2 lymphocytes. J Biol Chem (1997) 0.98
Alteration of mesodermal cell differentiation by EWS/FLI-1, the oncogene implicated in Ewing's sarcoma. Mol Cell Biol (2003) 0.94
BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib. Cancer Genet Cytogenet (2005) 0.90
Animal models of chronic myelogenous leukemia. Hematol Oncol Clin North Am (2004) 0.86
The biology of chronic myelogenous leukemia:mouse models and cell adhesion. Oncogene (2002) 0.86
Dissecting the molecular mechanism of chronic myelogenous leukemia using murine models. Leuk Lymphoma (2002) 0.81
The SH2 domain of bcr-Abl is not required to induce a murine myeloproliferative disease; however, SH2 signaling influences disease latency and phenotype. Blood (2001) 0.80
The diploid genome sequence of an Asian individual. Nature (2008) 46.29
A draft sequence of the rice genome (Oryza sativa L. ssp. indica). Science (2002) 42.78
Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med (2003) 26.05
The sequence and de novo assembly of the giant panda genome. Nature (2009) 15.76
Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev (2007) 13.05
Diverse somatic mutation patterns and pathway alterations in human cancers. Nature (2010) 10.83
TEAD mediates YAP-dependent gene induction and growth control. Genes Dev (2008) 9.88
Regulation of TORC1 by Rag GTPases in nutrient response. Nat Cell Biol (2008) 8.92
The genome of the cucumber, Cucumis sativus L. Nat Genet (2009) 8.19
An abundance of rare functional variants in 202 drug target genes sequenced in 14,002 people. Science (2012) 7.94
ZDOCK: an initial-stage protein-docking algorithm. Proteins (2003) 7.52
Gene discovery and annotation using LCM-454 transcriptome sequencing. Genome Res (2006) 7.10
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
A long-range Shh enhancer regulates expression in the developing limb and fin and is associated with preaxial polydactyly. Hum Mol Genet (2003) 6.82
Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med (2005) 6.58
Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination. Vaccine (2009) 6.30
PlasmoDB: the Plasmodium genome resource. A database integrating experimental and computational data. Nucleic Acids Res (2003) 6.19
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene (2002) 6.17
The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev (2010) 6.05
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med (2003) 5.96
SNP discovery via 454 transcriptome sequencing. Plant J (2007) 5.92
MicroRNA-mediated conversion of human fibroblasts to neurons. Nature (2011) 5.59
A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes Dev (2010) 5.38
The oyster genome reveals stress adaptation and complexity of shell formation. Nature (2012) 5.30
A porous supramolecular architecture from a copper(II) coordination polymer with a 3D four-connected 8(6) net. Inorg Chem (2003) 5.16
Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol (2007) 5.09
Immune recognition of Pseudomonas aeruginosa mediated by the IPAF/NLRC4 inflammasome. J Exp Med (2007) 4.95
Stability of the regulatory T cell lineage in vivo. Science (2010) 4.89
Identification of tendon stem/progenitor cells and the role of the extracellular matrix in their niche. Nat Med (2007) 4.80
Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A (2007) 4.77
The Plasmodium genome database. Nature (2002) 4.36
Cytokines and BMP-4 promote hematopoietic differentiation of human embryonic stem cells. Blood (2003) 3.98
Increased consumption of refined carbohydrates and the epidemic of type 2 diabetes in the United States: an ecologic assessment. Am J Clin Nutr (2004) 3.96
Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet (2006) 3.81
Genomic analysis reveals that Pseudomonas aeruginosa virulence is combinatorial. Genome Biol (2006) 3.75
Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev (2012) 3.48
ToxoDB: accessing the Toxoplasma gondii genome. Nucleic Acids Res (2003) 3.24
Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes Dev (2011) 3.15
A mouse knockout library for secreted and transmembrane proteins. Nat Biotechnol (2010) 3.09
Gene density, transcription, and insulators contribute to the partition of the Drosophila genome into physical domains. Mol Cell (2012) 3.08
Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res (2005) 3.08
Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene (2005) 3.05
Bone marrow-derived stem cells initiate pancreatic regeneration. Nat Biotechnol (2003) 3.02
Mouse neuroinvasive phenotype of West Nile virus strains varies depending upon virus genotype. Virology (2002) 2.96
Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol (2012) 2.91
Endothelial and hematopoietic cell fate of human embryonic stem cells originates from primitive endothelium with hemangioblastic properties. Immunity (2004) 2.89
Development of Foxp3(+) regulatory t cells is driven by the c-Rel enhanceosome. Immunity (2009) 2.84
Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol (2009) 2.84
Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy. Cancer Res (2011) 2.71
A highly sensitive CMOS digital Hall sensor for low magnetic field applications. Sensors (Basel) (2012) 2.69
Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. Blood (2006) 2.69
Mutations in myosin light chain kinase cause familial aortic dissections. Am J Hum Genet (2010) 2.67
Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res (2009) 2.65
Genomic characterization of non-O1, non-O139 Vibrio cholerae reveals genes for a type III secretion system. Proc Natl Acad Sci U S A (2005) 2.65
Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China. J Infect Dis (2009) 2.62
A review of EPAP nasal device therapy for obstructive sleep apnea syndrome. Sleep Breath (2014) 2.61
Role of ISG15 protease UBP43 (USP18) in innate immunity to viral infection. Nat Med (2004) 2.59
The antioxidant defense system Keap1-Nrf2 comprises a multiple sensing mechanism for responding to a wide range of chemical compounds. Mol Cell Biol (2008) 2.57
Noninvasive characterization of epicardial activation in humans with diverse atrial fibrillation patterns. Circulation (2010) 2.57
A Kir2.1 gain-of-function mutation underlies familial atrial fibrillation. Biochem Biophys Res Commun (2005) 2.55
The mitochondrial inner membrane protein mitofilin controls cristae morphology. Mol Biol Cell (2005) 2.53
Progressive histological damage in renal allografts is associated with expression of innate and adaptive immunity genes. Kidney Int (2011) 2.50
AILUN: reannotating gene expression data automatically. Nat Methods (2007) 2.47
High-resolution genomic and expression analyses of copy number alterations in breast tumors. Genes Chromosomes Cancer (2008) 2.46
1,1'-[(Hexane-1,6-diyldi-oxy)bis-(nitrilo-methyl-idyne)]dinaphthalene. Acta Crystallogr Sect E Struct Rep Online (2008) 2.45
Generation of hematopoietic repopulating cells from human embryonic stem cells independent of ectopic HOXB4 expression. J Exp Med (2005) 2.42
Selective sphingosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney. Am J Physiol Renal Physiol (2006) 2.39
Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol (2011) 2.38
Diethyl 3,8-dimethyl-4,7-diazadeca-2,8-dienedioate. Acta Crystallogr C (2004) 2.38
HIV/STD stigmatization fears as health-seeking barriers in China. AIDS Behav (2006) 2.37
PlasmoDB: the Plasmodium genome resource. An integrated database providing tools for accessing, analyzing and mapping expression and sequence data (both finished and unfinished). Nucleic Acids Res (2002) 2.37
Inflammation in acute kidney injury. Nephron Exp Nephrol (2008) 2.32
Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial. Lancet Neurol (2011) 2.27
Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci U S A (2007) 2.27
Role of interleukin 17 in inflammation, atherosclerosis, and vascular function in apolipoprotein e-deficient mice. Arterioscler Thromb Vasc Biol (2011) 2.27
TIPE2, a negative regulator of innate and adaptive immunity that maintains immune homeostasis. Cell (2008) 2.26
2,2-Dimethyl-2,3-dihydro-1-benzofuran-7-yl N-ethyl-carbamate. Acta Crystallogr Sect E Struct Rep Online (2009) 2.24
Renal ischemia-reperfusion injury and adenosine 2A receptor-mediated tissue protection: the role of CD4+ T cells and IFN-gamma. J Immunol (2006) 2.22
Regulatory T cells suppress innate immunity in kidney ischemia-reperfusion injury. J Am Soc Nephrol (2009) 2.18
The histone acetyltransferase MOF is a key regulator of the embryonic stem cell core transcriptional network. Cell Stem Cell (2012) 2.17
Release of hydrophobic molecules from polymer micelles into cell membranes revealed by Forster resonance energy transfer imaging. Proc Natl Acad Sci U S A (2008) 2.16
Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches. Blood (2006) 2.14
Influence of anchoring ligands and particle size on the colloidal stability and in vivo biodistribution of polyethylene glycol-coated gold nanoparticles in tumor-xenografted mice. Biomaterials (2009) 2.13
Differences between left and right ventricular chamber geometry affect cardiac vulnerability to electric shocks. Circ Res (2005) 2.11
Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1. Sci Transl Med (2011) 2.10
Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther (2004) 2.10
Interactions between genetic variants and breast cancer risk factors in the breast and prostate cancer cohort consortium. J Natl Cancer Inst (2011) 2.09
Increased expression of CYP17 and CYP11B1 in subclinical Cushing's syndrome due to adrenal adenomas. Int J Urol (2011) 2.07
A genome-wide association study in Han Chinese identifies new susceptibility loci for ankylosing spondylitis. Nat Genet (2011) 2.05
Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes. Am J Med (2012) 2.02
Characterization of growth and differentiation in a telomerase-immortalized human corneal epithelial cell line. Invest Ophthalmol Vis Sci (2005) 2.02
Sexually transmitted disease prevalence and characteristics of market vendors in eastern China. Sex Transm Dis (2003) 2.02
Regulation of tetrahydrobiopterin biosynthesis by shear stress. Circ Res (2007) 2.01
Elevated levels of hypoxia-inducible microRNA-210 in pre-eclampsia: new insights into molecular mechanisms for the disease. J Cell Mol Med (2012) 1.99
Baseline serum lactate dehydrogenase levels for patients treated with intensity-modulated radiotherapy for nasopharyngeal carcinoma: a predictor of poor prognosis and subsequent liver metastasis. Int J Radiat Oncol Biol Phys (2011) 1.99
Airborne trifluoroacetic acid and its fraction from the degradation of HFC-134a in Beijing, China. Environ Sci Technol (2014) 1.96
Analysis of 50 SNPs in CYP2D6, CYP2C19, CYP2C9, CYP3A4 and CYP1A2 by MALDI-TOF mass spectrometry in Chinese Han population. Forensic Sci Int (2010) 1.96
Ngari virus is a Bunyamwera virus reassortant that can be associated with large outbreaks of hemorrhagic fever in Africa. J Virol (2004) 1.93
Landscape determinants and remote sensing of anopheline mosquito larval habitats in the western Kenya highlands. Malar J (2006) 1.90